Standard

Желчнокаменная болезнь I стадии. Подходы к диагностике и лечению. Результаты исследования «Махаон». / Mekhtiev, S.N.; Mekhtieva, O.A.; Nikitin, I.G.; Okovityy, S.V.; Pavlov, C.S.; Bueverov, A.O.; Osipenko, M.F.; Turkina, S.V.; Vologzhanina, L.G.; Beloborodova, E.V.; Tsukanov, V.V.; Morozov, V.G.; Akhmedov, V.A.

в: ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV), Том 97, № 2, 26.03.2025, стр. 137-144.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

Harvard

Mekhtiev, SN, Mekhtieva, OA, Nikitin, IG, Okovityy, SV, Pavlov, CS, Bueverov, AO, Osipenko, MF, Turkina, SV, Vologzhanina, LG, Beloborodova, EV, Tsukanov, VV, Morozov, VG & Akhmedov, VA 2025, 'Желчнокаменная болезнь I стадии. Подходы к диагностике и лечению. Результаты исследования «Махаон»', ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV), Том. 97, № 2, стр. 137-144. https://doi.org/10.26442/00403660.2025.02.203160

APA

Mekhtiev, S. N., Mekhtieva, O. A., Nikitin, I. G., Okovityy, S. V., Pavlov, C. S., Bueverov, A. O., Osipenko, M. F., Turkina, S. V., Vologzhanina, L. G., Beloborodova, E. V., Tsukanov, V. V., Morozov, V. G., & Akhmedov, V. A. (2025). Желчнокаменная болезнь I стадии. Подходы к диагностике и лечению. Результаты исследования «Махаон». ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV), 97(2), 137-144. https://doi.org/10.26442/00403660.2025.02.203160

Vancouver

Mekhtiev SN, Mekhtieva OA, Nikitin IG, Okovityy SV, Pavlov CS, Bueverov AO и пр. Желчнокаменная болезнь I стадии. Подходы к диагностике и лечению. Результаты исследования «Махаон». ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV). 2025 Март 26;97(2):137-144. https://doi.org/10.26442/00403660.2025.02.203160

Author

Mekhtiev, S.N. ; Mekhtieva, O.A. ; Nikitin, I.G. ; Okovityy, S.V. ; Pavlov, C.S. ; Bueverov, A.O. ; Osipenko, M.F. ; Turkina, S.V. ; Vologzhanina, L.G. ; Beloborodova, E.V. ; Tsukanov, V.V. ; Morozov, V.G. ; Akhmedov, V.A. / Желчнокаменная болезнь I стадии. Подходы к диагностике и лечению. Результаты исследования «Махаон». в: ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV). 2025 ; Том 97, № 2. стр. 137-144.

BibTeX

@article{23724b7549f9456fa84aa08126de25f0,
title = "Желчнокаменная болезнь I стадии. Подходы к диагностике и лечению. Результаты исследования «Махаон»",
abstract = "Aim. To review the results of the open observational study Makhaon on the use of a fixed combination of glycyrrhizic acid (GA) and ursodeoxycholic acid (UDCA) (Phosphogliv Urso) for the treatment of abdominal pain, assessment of contractile function of the gallbladder and bile rheology in patients with stage I cholelithiasis. Materials and methods. The study included 330 subjects, 44.5% males and 55.5% females. The study participants were 18–70 years old, with a mean age of 43.8±0.6 years. In 2021–2022, patients were treated in 14 clinical centers in 10 cities of the Russian Federation: Moscow, St. Petersburg, Stavropol, Volgograd, Perm, Samara, Ufa, Omsk, Novosibirsk, Tomsk. All patients received Phosphogliv Urso (UDCA 250 mg + sodium glycyrrhizinate 35 mg), 1 capsule 3 times daily with food for 6 months. Results. Based on the clear improvement, therapy with a combination of GA and UDCA has demonstrated high efficacy and safety and appears to be optimal for the treatment of abdominal pain, improvement of the contractile function of the gallbladder, and physicochemical properties of bile in patients with stage I cholelithiasis. Conclusion. Treating all variants of baseline changes in the bile rheology is an urgent task of modern biliology. Universal drugs for stage I cholelithiasis are UDCA and its fixed combination with GA. {\textcopyright} 2025 Elsevier B.V., All rights reserved.",
keywords = "biliary sludge, cholelithiasis, endosonography, functional biliary disorders, gallbladder, glycyrrhizic acid, microcholelithiasis, pancreatitis, Phosphogliv Urso, ursodeoxycholic acid, cholagogue, abdominal pain, adolescent, adult, aged, clinical trial, diagnosis, drug combination, drug therapy, epidemiology, etiology, female, human, male, middle aged, multicenter study, pathophysiology, Russian Federation, treatment outcome, Abdominal Pain, Adolescent, Adult, Aged, Cholagogues and Choleretics, Cholelithiasis, Drug Combinations, Female, Glycyrrhizic Acid, Humans, Male, Middle Aged, Russia, Treatment Outcome, Ursodeoxycholic Acid",
author = "S.N. Mekhtiev and O.A. Mekhtieva and I.G. Nikitin and S.V. Okovityy and C.S. Pavlov and A.O. Bueverov and M.F. Osipenko and S.V. Turkina and L.G. Vologzhanina and E.V. Beloborodova and V.V. Tsukanov and V.G. Morozov and V.A. Akhmedov",
note = "Export Date: 01 November 2025; Cited By: 0; Correspondence Address: S.N. Mekhtiev; Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation; email: sabirm@mail.ru; CODEN: TEARA",
year = "2025",
month = mar,
day = "26",
doi = "10.26442/00403660.2025.02.203160",
language = "русский",
volume = "97",
pages = "137--144",
journal = "ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)",
issn = "0040-3660",
publisher = "Медицина",
number = "2",

}

RIS

TY - JOUR

T1 - Желчнокаменная болезнь I стадии. Подходы к диагностике и лечению. Результаты исследования «Махаон»

AU - Mekhtiev, S.N.

AU - Mekhtieva, O.A.

AU - Nikitin, I.G.

AU - Okovityy, S.V.

AU - Pavlov, C.S.

AU - Bueverov, A.O.

AU - Osipenko, M.F.

AU - Turkina, S.V.

AU - Vologzhanina, L.G.

AU - Beloborodova, E.V.

AU - Tsukanov, V.V.

AU - Morozov, V.G.

AU - Akhmedov, V.A.

N1 - Export Date: 01 November 2025; Cited By: 0; Correspondence Address: S.N. Mekhtiev; Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation; email: sabirm@mail.ru; CODEN: TEARA

PY - 2025/3/26

Y1 - 2025/3/26

N2 - Aim. To review the results of the open observational study Makhaon on the use of a fixed combination of glycyrrhizic acid (GA) and ursodeoxycholic acid (UDCA) (Phosphogliv Urso) for the treatment of abdominal pain, assessment of contractile function of the gallbladder and bile rheology in patients with stage I cholelithiasis. Materials and methods. The study included 330 subjects, 44.5% males and 55.5% females. The study participants were 18–70 years old, with a mean age of 43.8±0.6 years. In 2021–2022, patients were treated in 14 clinical centers in 10 cities of the Russian Federation: Moscow, St. Petersburg, Stavropol, Volgograd, Perm, Samara, Ufa, Omsk, Novosibirsk, Tomsk. All patients received Phosphogliv Urso (UDCA 250 mg + sodium glycyrrhizinate 35 mg), 1 capsule 3 times daily with food for 6 months. Results. Based on the clear improvement, therapy with a combination of GA and UDCA has demonstrated high efficacy and safety and appears to be optimal for the treatment of abdominal pain, improvement of the contractile function of the gallbladder, and physicochemical properties of bile in patients with stage I cholelithiasis. Conclusion. Treating all variants of baseline changes in the bile rheology is an urgent task of modern biliology. Universal drugs for stage I cholelithiasis are UDCA and its fixed combination with GA. © 2025 Elsevier B.V., All rights reserved.

AB - Aim. To review the results of the open observational study Makhaon on the use of a fixed combination of glycyrrhizic acid (GA) and ursodeoxycholic acid (UDCA) (Phosphogliv Urso) for the treatment of abdominal pain, assessment of contractile function of the gallbladder and bile rheology in patients with stage I cholelithiasis. Materials and methods. The study included 330 subjects, 44.5% males and 55.5% females. The study participants were 18–70 years old, with a mean age of 43.8±0.6 years. In 2021–2022, patients were treated in 14 clinical centers in 10 cities of the Russian Federation: Moscow, St. Petersburg, Stavropol, Volgograd, Perm, Samara, Ufa, Omsk, Novosibirsk, Tomsk. All patients received Phosphogliv Urso (UDCA 250 mg + sodium glycyrrhizinate 35 mg), 1 capsule 3 times daily with food for 6 months. Results. Based on the clear improvement, therapy with a combination of GA and UDCA has demonstrated high efficacy and safety and appears to be optimal for the treatment of abdominal pain, improvement of the contractile function of the gallbladder, and physicochemical properties of bile in patients with stage I cholelithiasis. Conclusion. Treating all variants of baseline changes in the bile rheology is an urgent task of modern biliology. Universal drugs for stage I cholelithiasis are UDCA and its fixed combination with GA. © 2025 Elsevier B.V., All rights reserved.

KW - biliary sludge

KW - cholelithiasis

KW - endosonography

KW - functional biliary disorders

KW - gallbladder

KW - glycyrrhizic acid

KW - microcholelithiasis

KW - pancreatitis

KW - Phosphogliv Urso

KW - ursodeoxycholic acid

KW - cholagogue

KW - abdominal pain

KW - adolescent

KW - adult

KW - aged

KW - clinical trial

KW - diagnosis

KW - drug combination

KW - drug therapy

KW - epidemiology

KW - etiology

KW - female

KW - human

KW - male

KW - middle aged

KW - multicenter study

KW - pathophysiology

KW - Russian Federation

KW - treatment outcome

KW - Abdominal Pain

KW - Adolescent

KW - Adult

KW - Aged

KW - Cholagogues and Choleretics

KW - Cholelithiasis

KW - Drug Combinations

KW - Female

KW - Glycyrrhizic Acid

KW - Humans

KW - Male

KW - Middle Aged

KW - Russia

KW - Treatment Outcome

KW - Ursodeoxycholic Acid

UR - https://www.mendeley.com/catalogue/419ce236-803f-311a-a49d-0672283013f7/

U2 - 10.26442/00403660.2025.02.203160

DO - 10.26442/00403660.2025.02.203160

M3 - статья

VL - 97

SP - 137

EP - 144

JO - ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)

JF - ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)

SN - 0040-3660

IS - 2

ER -

ID: 143613303